Ischemic Stroke Clinical Trial
Official title:
Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patients With Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial
Verified date | August 2020 |
Source | Thammasat University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with acute ischemic stroke will be divided into 2 groups by double-blind,
randomized, and controlled trial. Personality and past history of the patients will be
recorded after the patients signed inform consent. The patient will be collected blood among
10 cc. for measurement biomarker in serum that related plaque stability for baseline and
obtained neurological examination for baseline.
The patients must be take pills for 180 days by randomized code number on pill box, and
patients must be turn into the site for follow up visit at Day 90 and Day 180. All visits of
the patients will be collected blood among 10 cc. for measurement biomarker in serum that
related plaque stability and obtained neurological examination.
Next, the data will be separated with code number for divided group into 2 groups. Group 1 is
simvastatin 10 mg per day treatment (n=36) and Group 2 is simvastatin 40 mg per day
treatment. Finally, all data of each group will be calculated mean ± standard deviation, and
compared by statistical analysis.
Status | Completed |
Enrollment | 64 |
Est. completion date | December 31, 2015 |
Est. primary completion date | October 4, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patient with acute ischemic stroke has symptom onset less than 24 hours. - Patient has 18 to 85 years old. - Patient has been obtained describe the study and sign on informed consent. Exclusion Criteria: - Patient has indication for simvastatin or ya-hom-navakote. - Patient has pre-stroke mRS score more than 1. - Patient was enrolled in other study within 30 days ago. - Researchers consider that could be harmed by the participants or have certain conditions that could affect the participation in research, such as last stage of cancer. - According to medical research suggests that patients unable to cooperate in research or inappropriate in joint research with other causes. - Conscious level has >2 scores on question 2 of NIHSS. - Platelet counts have less than 100,000 cells per cubic milliliter. - Hematocrit has less than 0.25 - Blood sugar (BS) has less than 60 mg/dl or more than 200 ml/dl or between 200 and 300 mg/dl and treated with diabetes drug until the BS levels have less than 200 mg/dl can include for the project before receive the researched drug. - Patient with uncontrolled hypertension by measure systolic blood pressure (SBP) has more than 200 mmHg and/or diastolic blood pressure (DBP) has more than 110 mmHg before receive the researched drug or patient that receive aggressive treatment. - Patient with others stroke or severe head injury within 6 weeks before enrolled to the project. - Patient is received severe surgery within 14 days before enrolled to the project. - Patient has seizure with acute ischemic stroke. - Patient has acute myocardial infarction (AMI) or coronary heart disease (CHD) within 3 weeks before enrolled to the project. - Patient who receives lower-lipid level drug i.e. Ezetrol, Fenofibrate, Gemfibrosil, and Niacin or statin drugs i.e. Atorvastatin and Pitavastatin. - Patient has increasing liver enzyme level or liver abnormal disease. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Thammasat University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | vascular oxidative stress by measuring Soluble lectin-like oxidized low density lipoprotein receptor-1 and Nitric oxide levels | Soluble lectin-like oxidized low density lipoprotein receptor-1 in microgram/milliliter and Nitric oxide in micromole/liter is biomarkers of vascular oxidative stress. | 180 days | |
Secondary | neurological outcomes by measuring National Institutes of Health Stroke Scale (NIHSS) | NIHSS is a assessment of clinical neurology in stroke | 180 days | |
Secondary | neurological outcomes by modified Rankin's Scale (mRS) | mRS is a assessment of clinical neurology in stroke | 180 days | |
Secondary | neurological outcomes by measuring Barthel's index | Barthel's index is a assessment of clinical neurology in stroke | 180 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Not yet recruiting |
NCT01923818 -
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
|
Phase 2/Phase 3 |